# Artivion (AORT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/AORT
## Company Profile
- Ticker: AORT
- Exchange: NYSE
- Sector: MedTech
- Location: United States
- Tags: MedTech
## Stock Data
- Close: 28.64 USD
- Market cap: 991255207.0000001 USD
- Last updated: 2026-08-12
## Business Overview
### Aortic-Disease Technologies
Artivion develops medical devices and implantable tissues for complex aortic and cardiac surgery. Its portfolio is designed around the needs of cardiac and vascular surgeons treating life-threatening aortic disease.
### Surgical Products
The company supplies aortic stent grafts, surgical adhesives, mechanical heart valves and preserved cardiac and vascular tissues. These products support both open and hybrid procedures.
### Endovascular Expansion
Artivion exercised its option to acquire Endospan, developer of the FDA-approved NEXUS Aortic Arch System. The transaction would expand Artivion into endovascular treatment of aortic-arch disease alongside its existing surgical portfolio.
## Why The Stock Is Moving

As of Aug 12, 2026, AORT closed up 0.88% at $28.64. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-06 20:05 EST — [Artivion Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/AORT/artivion-reports-second-quarter-2026-financial-results-66273319) — Source: Artivion
- 2026-07-28 20:10 EST — [Artivion to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/AORT/artivion-to-participate-in-upcoming-investor-conferences-5ff1d4ef) — Source: Artivion
- 2026-07-23 20:10 EST — [Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-second-quart-b684f865) — Source: Artivion
- 2026-06-29 11:00 EST — [Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis](https://biopharmsignal.com/news/AORT/artivion-announces-u-s-fda-approval-of-the-amds-hybrid-prosthesis-15da88f3) — Source: Artivion
- 2026-06-10 20:10 EST — [Artivion to Participate in the 2026 Truist Securities MedTech Conference](https://biopharmsignal.com/news/AORT/artivion-to-participate-in-the-2026-truist-securities-medtech-conference-e00c2184) — Source: Artivion